Safety, clinical activity, pharmacodynamics, and pharmacokinetics of IMU-856, a SIRT6 modulator, in coeliac disease: a first-in-human, randomised, double-blind, placebo-controlled, phase 1 trial

Authors: A James M Daveson, Richard Stubbs, Thomas M Polasek, Jorma Isola, Robert Anderson, Jason A Tye-Din, Mark Schoeman, Claudette Lionnet, Swee Lin Chen Yi Mei, Jelena Mihajlović, Martina Wirth, Evelyn Peelen, Amelie Schreieck, Hella Kohlhof, Daniel Vitt, Andreas Muehler, Franziska Buriánek

Published: 2024-11-07

DOI: 10.1016/s2468-1253(24)00248-6

Source: Full article

---

Abstract

No abstract found.